These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Plasminogen activator inhibitor-1 is associated with impaired endothelial function in women with systemic lupus erythematosus. Somers EC; Marder W; Kaplan MJ; Brook RD; McCune WJ Ann N Y Acad Sci; 2005 Jun; 1051():271-80. PubMed ID: 16126968 [TBL] [Abstract][Full Text] [Related]
4. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus. Glas-Greenwalt P; Kant KS; Allen C; Pollak VE J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000 [TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Jurado M; Páramo JA; Gutierrez-Pimentel M; Rocha E Thromb Haemost; 1992 Nov; 68(5):516-20. PubMed ID: 1455397 [TBL] [Abstract][Full Text] [Related]
6. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients. Sultan Y; Harris A; Strauch G; Venot A; De Lauture D J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470 [TBL] [Abstract][Full Text] [Related]
7. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Siegbahn A; Ruusuvaara L Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043 [TBL] [Abstract][Full Text] [Related]
8. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. Francis RB; McGehee WG; Feinstein DI Thromb Haemost; 1988 Jun; 59(3):412-4. PubMed ID: 3142079 [TBL] [Abstract][Full Text] [Related]
9. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. Munkvad S Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763 [TBL] [Abstract][Full Text] [Related]
10. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus. Heshmat NM; El-Kerdany TH Pediatr Allergy Immunol; 2007 Jun; 18(4):346-53. PubMed ID: 17346298 [TBL] [Abstract][Full Text] [Related]
11. Predisposing factors to thrombosis in systemic lupus erythematosus: possible relation to endothelial cell damage. Angles-Cano E; Sultan Y; Clauvel JP J Lab Clin Med; 1979 Aug; 94(2):312-23. PubMed ID: 458249 [TBL] [Abstract][Full Text] [Related]
19. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease. Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383 [TBL] [Abstract][Full Text] [Related]
20. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]